[Geneva, 5th June 2025] – Clearview Market Insights (CVMI) forecasts that the global arbovirus testing market will grow from USD 1.84 billion in 2024 to USD 4.67 billion by 2031, achieving a robust compound annual growth rate (CAGR) of 14.2 percent. This expansion is driven by an increase in vector-borne disease outbreaks, heightened investment in public health surveillance, and rapid advancements in field-deployable diagnostics.
“Arbovirus testing is no longer seasonal or regional—it’s a core component of global outbreak intelligence and pandemic prevention,” said Dr. Martin Alvarez, infectious disease diagnostics lead at CVMI. “The convergence of AI, mobile diagnostics, and next-gen serology is transforming how health systems detect, report, and respond to vector-borne threats.”
Request Sample @ https://clearviewmarketinsights.com/report-details/global-arbovirus-testing-market/
Key Numbers
- 2024 Market Value: USD 1.84 billion
- 2031 Market Value: USD 4.67 billion
- Seven-Year CAGR: 14.2 percent
- Dengue Testing Share (2024): 41%
- Asia-Pacific Market Share: 39%
Market Drivers
- Climate-driven spread of mosquitoes and ticks
- Global health funding for early detection
- Urban travel and international disease transmission
- WHO, CDC, and PAHO-led surveillance initiatives
- Demand for rapid, field-ready diagnostics
Company Highlights
- Abbott rolled out dual-target RDTs across high-burden countries.
- Roche added Liat-compatible arbovirus test panels for fast deployment.
- Thermo Fisher established mobile labs in the Caribbean with portable qPCR.
- Bio-Rad launched ELISA tools that distinguish between co-circulating flaviviruses.
Regional Insights
- Asia-Pacific: Dengue and chikungunya dominate public testing programs.
- Latin America: Brazil, Colombia, and Peru invest in decentralized arbovirus labs.
- Africa: Surveillance rising for Rift Valley Fever and West Nile virus.
- North America/Europe: Focus on travel medicine and integrated vector surveillance.
2024–2025 Milestones
Quarter | Event | Impact |
Q1 2024 | WHO prequalifies 2 new multiplex kits | Accelerates field deployment in Southeast Asia |
Q2 2024 | Thermo Fisher launches mobile PCR labs | Caribbean islands improve real-time detection capacity |
Q3 2024 | Bio-Rad introduces differential IgM panels | Boosts diagnostic accuracy during co-outbreaks |
Q1 2025 | Qiagen expands vector surveillance portfolio | Strengthens qPCR diagnostics in Africa and LATAM |
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights
Clearview Market Insights is a leading provider of global infectious disease diagnostics research, offering forward-looking insights across more than 100 disease surveillance and laboratory technology markets. We assist stakeholders in aligning innovation with public health priorities through data, forecasting, and strategic guidance.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
